This important hormone-like regulator was not investigated in this study, yet others have shown that serum FGF19 was increased in patients with NASH-HCC and associated with tumor markers and with NAFLD progression [77]. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatotic liver disease.